BioSpace News Archive

SeqLL Inc. announced its operating and financial results for the first quarter ended March 31, 2023.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.

Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting.

Jaguar Health, Inc. today announced that it has completed enrolling the target number of 256 patients in the Company’s global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy.

ValGenesis, Inc. today announced that an elite biotechnology company selected ValGenesis VLMS for digitizing multiple validation processes across the organization.

The Insight Partners published latest research report on “Molecular Diagnostics Market Growth Report, Size, Share, Trends and Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Area; Technology; Product and Services; End User and Geography”

The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to elacestrant in upcoming congresses.

Led by researchers from NYU Grossman School of Medicine and University of Szeged in Hungary, a new study in mice and rats found that restoring certain signals in a brain region that processes smells countered depression.

The Sobi® AGM was convened on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions.